Use este identificador para citar ou linkar para este item:
https://www.arca.fiocruz.br/handle/icict/39717
Tipo de documento
ArtigoDireito Autoral
Acesso aberto
Coleções
- IOC - Artigos de Periódicos [12642]
Metadata
Mostrar registro completo
CELL PROLIFERATION AND INTERFERON-GAMMA RESPONSE TO RECOMBINANT MBP-3, NARL, MT-10.3, AND 16 KDA MYCOBACTERIUM TUBERCULOSIS ANTIGENS IN BRAZILIAN TUBERCULOSIS PATIENTS
Autor(es)
Afiliação
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Hospital Municipal Souza Aguiar. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto Microbiologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto Microbiologia. Rio de Janeiro, RJ, Brasil.
Lionex Immuno Diagnostic and Therapeutic. Braunchweig, Germany.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto Microbiologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Hospital Municipal Souza Aguiar. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto Microbiologia. Rio de Janeiro, RJ, Brasil.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto Microbiologia. Rio de Janeiro, RJ, Brasil.
Lionex Immuno Diagnostic and Therapeutic. Braunchweig, Germany.
Universidade Federal do Rio de Janeiro. Hospital Universitário Clementino Fraga Filho. Instituto Microbiologia. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Oswaldo Cruz. Departamento de Micobacterioses. Rio de Janeiro, RJ, Brasil.
Resumo em Inglês
Human pulmonary tuberculosis (TB) is a worldwide public health problem. In resistant individuals, control of the infection mainly requires development of a Th1 cell immune response with production of cytokines, of which interferon-gamma (IFN-gamma)plays an important role. Several antigens from Mycobacterium tuberculosis complex has been described for use in vaccine development or for diagnostic purposes, however little evaluation has been done in endemic area for TB. The proliferative and IFN-gamma human T cell immune responses, to four recombinant proteins (MBP-3, NarL, MT-10.3, 16 kDa) and PPD, of 38 Brazilian TB patients (6 untreated and 32 treated) and 67 controls (38 positive and 29 negative tuberculin skin test - TST) were compared. The highest reactivity mean rate was obtained with PPD followed by 16 kDa in TB patients. While most of the patients (87%) and controls (> 64%) respond to the PPD, 16 kDa was more specifically recognized (> 21%) although less sensitive (54%). When TB patients were divided according to treatment status, opposite to PPD, higher average level of IFN-gamma was induced by 16 kDa in untreated (505 pg/ml) compared to treated TB patients and TST+ (269.8 pg/ml x 221.6 pg/ml, respectively), although the difference was not significant. These data show that in contrast with the other recombinant proteins, the stimulatory potency of 16 kDa to induce proliferative and INF-gamma response was more effective and is more recognized by active TB untreated patients, eliciting in control individuals a more selective immune response than PPD.
Compartilhar